Your browser doesn't support javascript.
loading
Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD).
De Filippi, Paola; Errichiello, Edoardo; Toscano, Antonio; Mongini, Tiziana; Moggio, Maurizio; Ravaglia, Sabrina; Filosto, Massimiliano; Servidei, Serenella; Musumeci, Olimpia; Giannini, Fabio; Piperno, Alberto; Siciliano, Gabriele; Ricci, Giulia; Di Muzio, Antonio; Rigoldi, Miriam; Tonin, Paola; Croce, Michele Giovanni; Pegoraro, Elena; Politano, Luisa; Maggi, Lorenzo; Telese, Roberta; Lerario, Alberto; Sancricca, Cristina; Vercelli, Liliana; Semplicini, Claudio; Pasanisi, Barbara; Bembi, Bruno; Dardis, Andrea; Palmieri, Ilaria; Cereda, Cristina; Valente, Enza Maria; Danesino, Cesare.
Afiliação
  • De Filippi P; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Errichiello E; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Toscano A; Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
  • Mongini T; ERN-NMD Center of Messina for Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
  • Moggio M; Neuromuscular Unit, Department of Neuroscience RLM, University of Torino, 10126 Torino, Italy.
  • Ravaglia S; Neuromuscular and Rare Diseases Unit, BioBank of Skeletal Muscle, Peripheral Nerve, DNA and Dino Ferrari Center, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, 20100 Milan, Italy.
  • Filosto M; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Servidei S; Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, 25121 Brescia, Italy.
  • Musumeci O; Department of Neuroscience, Catholic University, 00100 Rome, Italy.
  • Giannini F; Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
  • Piperno A; Department of Medical, Surgical and Neurological Sciences, University of Siena, "Le Scotte" Hospital, 53100 Siena, Italy.
  • Siciliano G; Fondazione IRCCS San Gerardo, Centro Ricerca Testamenti, Monza-European Reference Network-MetabERN, 20900 Monza, Italy.
  • Ricci G; Department of Clinical and Experimental Medicine, Neurological Clinics, University of Pisa, 56100 Pisa, Italy.
  • Di Muzio A; Department of Clinical and Experimental Medicine, Neurological Clinics, University of Pisa, 56100 Pisa, Italy.
  • Rigoldi M; Centre for Neuromuscular Disease, CeSI, University "G. d'Annunzio", 66100 Chieti, Italy.
  • Tonin P; Dipartimento di Ricerca Malattie Rare, Istituto Mario Negri IRCCS, 24020 Ranica, Italy.
  • Croce MG; Department of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, 37100 Verona, Italy.
  • Pegoraro E; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Politano L; Department of Neurosciences, University of Padova, 35100 Padova, Italy.
  • Maggi L; Cardiomiologia e Genetica Medica, Dipartimento di Medicina Sperimentale, Seconda Università di Napoli, 80100 Napoli, Italy.
  • Telese R; Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20100 Milano, Italy.
  • Lerario A; Centre for Neuromuscular Disease, CeSI, University "G. d'Annunzio", 66100 Chieti, Italy.
  • Sancricca C; Neuromuscular and Rare Diseases Unit, BioBank of Skeletal Muscle, Peripheral Nerve, DNA and Dino Ferrari Center, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, 20100 Milan, Italy.
  • Vercelli L; Department of Neuroscience, Catholic University, 00100 Rome, Italy.
  • Semplicini C; Neuromuscular Unit, Department of Neuroscience RLM, University of Torino, 10126 Torino, Italy.
  • Pasanisi B; Department of Neurosciences, University of Padova, 35100 Padova, Italy.
  • Bembi B; Cardiomiologia e Genetica Medica, Dipartimento di Medicina Sperimentale, Seconda Università di Napoli, 80100 Napoli, Italy.
  • Dardis A; Regional Coordinator Centre for Rare Diseases, University Hospital "Santa Maria della Misericordia", 33100 Udine, Italy.
  • Palmieri I; Regional Coordinator Centre for Rare Diseases, University Hospital "Santa Maria della Misericordia", 33100 Udine, Italy.
  • Cereda C; IRCCS Mondino Foundation, 27100 Pavia, Italy.
  • Valente EM; Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
  • Danesino C; Center of Functional Genomic and Rare Diseases-Buzzi Children's Hospital, 20100 Milano, Italy.
Curr Issues Mol Biol ; 45(4): 2847-2860, 2023 Apr 01.
Article em En | MEDLINE | ID: mdl-37185710
Pompe disease (PD) is a monogenic autosomal recessive disorder caused by biallelic pathogenic variants of the GAA gene encoding lysosomal alpha-glucosidase; its loss causes glycogen storage in lysosomes, mainly in the muscular tissue. The genotype-phenotype correlation has been extensively discussed, and caution is recommended when interpreting the clinical significance of any mutation in a single patient. As there is no evidence that environmental factors can modulate the phenotype, the observed clinical variability in PD suggests that genetic variants other than pathogenic GAA mutations influence the mechanisms of muscle damage/repair and the overall clinical picture. Genes encoding proteins involved in glycogen synthesis and catabolism may represent excellent candidates as phenotypic modifiers of PD. The genes analyzed for glycogen synthesis included UGP2, glycogenin (GYG1-muscle, GYG2, and other tissues), glycogen synthase (GYS1-muscle and GYS2-liver), GBE1, EPM2A, NHLRC1, GSK3A, and GSK3B. The only enzyme involved in glycogen catabolism in lysosomes is α-glucosidase, which is encoded by GAA, while two cytoplasmic enzymes, phosphorylase (PYGB-brain, PGL-liver, and PYGM-muscle) and glycogen debranching (AGL) are needed to obtain glucose 1-phosphate or free glucose. Here, we report the potentially relevant variants in genes related to glycogen synthesis and catabolism, identified by whole exome sequencing in a group of 30 patients with late-onset Pompe disease (LOPD). In our exploratory analysis, we observed a reduced number of variants in the genes expressed in muscles versus the genes expressed in other tissues, but we did not find a single variant that strongly affected the phenotype. From our work, it also appears that the current clinical scores used in LOPD do not describe muscle impairment with enough qualitative/quantitative details to correlate it with genes that, even with a slightly reduced function due to genetic variants, impact the phenotype.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article